For Cubist's Cidecin, sales will be even smaller--only a few hundred million dollars.

FORBES: Antibiotic Breakthroughs Fall Short

Cubist's injectible antibiotic Cidecin targets S. aureus and similarly resistant bugs in hospitals.

FORBES: A Better Antibiotic?

Cubist fixed the problem and sees Cidecin as an important new medicine that could significantly boost the tiny Cambridge, Mass.

FORBES: Antibiotic Breakthroughs Fall Short

Meanwhile, Cubist's injectible entrant, Cidecin, is incredibly powerful against some bacteria but will be useful mainly for infections that occur in hospitals.

FORBES: Antibiotic Breakthroughs Fall Short

Now he is watching anti-bacterial drugs make a bit of a comeback, and may even be leading the way with Cubist's Cidecin.

FORBES: Magazine Article

Cubist Pharmaceuticals in Lexington, Mass. is waiting for approval on Cidecin, an injection for treating hospital-acquired skin infections, which was discovered and then mothballed by Eli Lilly.

FORBES: Bug Wars

Glivec became Gleevec, Cidecin became Cubicin, and Antegren became Tysabri (those are for cancer, bacterial infection, and multiple sclerosis, respectively.) But changes in generic name seem less common.

FORBES: Why Pfizer's Biggest Experimental Drug Got A Name Change